Development of AAV-AXN-007 gene therapy to treat glaucoma.

开发 AAV-AXN-007 基因疗法来治疗青光眼。

基本信息

  • 批准号:
    10547231
  • 负责人:
  • 金额:
    $ 29.88万
  • 依托单位:
  • 依托单位国家:
    美国
  • 项目类别:
  • 财政年份:
    2022
  • 资助国家:
    美国
  • 起止时间:
    2022-09-01 至 2024-02-29
  • 项目状态:
    已结题

项目摘要

Development of AAV-AXN-007 gene therapy to treat Glaucoma Abstract: Glaucoma represents the world’s leading cause of irreversible blindness, with its prevalence increasing as the population ages. Vision loss in glaucoma is caused by a progressive degeneration of retinal ganglion cells (RGCs), yet there are no approved therapies that can directly prevent RGC loss. Because elevated intraocular pressure (IOP) is only known modifiable risk factor, current standard of care involves IOP-lowering treatments via pharmacological and surgical approaches. This chronic, progressive, age-related neurodegenerative disorder is an urgent, unmet, global and growing problem, with the number of people worldwide suffering with glaucoma expected to double to ~120 million by 2040, and the annual medical costs of glaucoma in US projected treble to >$17 billion by 2050. To address this escalating medical and socioeconomic burden, and to improve lives of glaucoma patients and their families, novel disease-modifying therapies are needed. Progressive RGC degeneration in glaucoma is thought to result from an intrinsic sensitivity of RGCs that over time succumb to the chronic pathological stresses of this complex neurodegenerative disease. Intervening during this time period in the remaining RGCs of glaucoma patients could prevent their degeneration. To identify new therapeutic targets, an unbiased in vivo AAV2-CRISPR/Cas9 screen of >2,000 genes (tested one-by-one) for RGC neuroprotection in the mouse optic nerve crush model was conducted. This forward genetic screen in an animal model of optic neuropathy discovered a neuroprotective hit gene that, when targeted with AAV2-sgRNA, could prevent RGCs from degeneration following axon damage. Additionally, this pathway has been reported to be activated in post-mortem retinal tissue from glaucoma patients and after optic nerve damage. In this SBIR application, our goal is to validate and test a novel neuroprotective target and AAV2-AXN-007 gene therapeutic approach for its ability to protect RGCs, their axons and visual function in the widely-used mouse microbead occlusion model of glaucoma.
AAV-AXN-007基因治疗青光眼的研究进展 摘要: 青光眼是世界上导致不可逆失明的主要原因,其患病率随着年龄的增长而增加。 人口老龄化。青光眼的视力丧失是由视网膜神经节细胞的进行性变性引起的 然而,目前还没有批准的治疗方法可以直接预防RGC损失。因为眼内压升高 眼压(IOP)是唯一已知的可改变的风险因素,目前的标准治疗包括降低IOP的治疗 通过药理学和手术方法。这种慢性的,进行性的,与年龄相关的神经退行性疾病 疾病是一个紧迫的、未得到解决的、全球性的和日益严重的问题,全世界有许多人患有 到2040年,青光眼预计将翻一番,达到约1.2亿,美国青光眼的年度医疗费用 预计到2050年将增加两倍至170亿美元。为了解决日益加重的医疗和社会经济负担, 为了改善青光眼患者及其家庭生活,需要新的疾病改善疗法。 青光眼中进行性RGC变性被认为是RGC内在敏感性的结果 随着时间的推移屈服于这种复杂的神经退行性疾病的慢性病理压力。 在这段时间内对青光眼患者剩余的RGC进行干预可以防止其 退化为了识别新的治疗靶点,进行了> 2,000的公正体内AAV 2-CRISPR/Cas9筛选 在小鼠视神经挤压模型中进行RGC神经保护的基因(逐个测试)。 在视神经病变的动物模型中,这种正向遗传筛选发现了一种神经保护性命中基因, 当用AAV 2-sgRNA靶向时,可以防止RGCs在轴突损伤后的变性。 此外,据报道,该途径在青光眼的死后视网膜组织中被激活 患者和视神经损伤后。在这个SBIR应用程序中,我们的目标是验证和测试一种新的 神经保护性靶标和AAV 2-AXN-007基因治疗方法,其保护RGC的能力, 广泛使用的小鼠微珠阻塞青光眼模型中的轴突和视觉功能。

项目成果

期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ monograph.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ sciAawards.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ conferencePapers.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ patent.updateTime }}

Shane Hegarty其他文献

Shane Hegarty的其他文献

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

{{ truncateString('Shane Hegarty', 18)}}的其他基金

Development of oral KCC2 enhancer drug for treatment of painful diabetic neuropathy
开发用于治疗疼痛性糖尿病神经病变的口服 KCC2 增强剂药物
  • 批准号:
    10699218
  • 财政年份:
    2023
  • 资助金额:
    $ 29.88万
  • 项目类别:

相似海外基金

Kilohertz volumetric imaging of neuronal action potentials in awake behaving mice
清醒行为小鼠神经元动作电位的千赫兹体积成像
  • 批准号:
    10515267
  • 财政年份:
    2022
  • 资助金额:
    $ 29.88万
  • 项目类别:
Signal processing in horizontal cells of the mammalian retina – coding of visual information by calcium and sodium action potentials
哺乳动物视网膜水平细胞的信号处理 â 通过钙和钠动作电位编码视觉信息
  • 批准号:
    422915148
  • 财政年份:
    2019
  • 资助金额:
    $ 29.88万
  • 项目类别:
    Research Grants
CAREER: Resolving action potentials and high-density neural signals from the surface of the brain
职业:解析来自大脑表面的动作电位和高密度神经信号
  • 批准号:
    1752274
  • 财政年份:
    2018
  • 资助金额:
    $ 29.88万
  • 项目类别:
    Continuing Grant
Development of Nanosheet-Based Wireless Probes for Multi-Simultaneous Monitoring of Action Potentials and Neurotransmitters
开发基于纳米片的无线探针,用于同时监测动作电位和神经递质
  • 批准号:
    18H03539
  • 财政年份:
    2018
  • 资助金额:
    $ 29.88万
  • 项目类别:
    Grant-in-Aid for Scientific Research (B)
Population Imaging of Action Potentials by Novel Two-Photon Microscopes and Genetically Encoded Voltage Indicators
通过新型双光子显微镜和基因编码电压指示器对动作电位进行群体成像
  • 批准号:
    9588470
  • 财政年份:
    2018
  • 资助金额:
    $ 29.88万
  • 项目类别:
Enhanced quantitative imaging of compound action potentials in multi-fascicular peripheral nerve with fast neural Electrical Impedance Tomography enabled by 3D multi-plane softening bioelectronics
通过 3D 多平面软化生物电子学实现快速神经电阻抗断层扫描,增强多束周围神经复合动作电位的定量成像
  • 批准号:
    10009724
  • 财政年份:
    2018
  • 资助金额:
    $ 29.88万
  • 项目类别:
Enhanced quantitative imaging of compound action potentials in multi-fascicular peripheral nerve with fast neural Electrical Impedance Tomography enabled by 3D multi-plane softening bioelectronics
通过 3D 多平面软化生物电子学实现快速神经电阻抗断层扫描,增强多束周围神经复合动作电位的定量成像
  • 批准号:
    10467225
  • 财政年份:
    2018
  • 资助金额:
    $ 29.88万
  • 项目类别:
Fast high-resolution deep photoacoustic tomography of action potentials in brains
大脑动作电位的快速高分辨率深度光声断层扫描
  • 批准号:
    9423398
  • 财政年份:
    2017
  • 资助金额:
    $ 29.88万
  • 项目类别:
Noval regulatory mechanisms of axonal action potentials
轴突动作电位的新调节机制
  • 批准号:
    16K07006
  • 财政年份:
    2016
  • 资助金额:
    $ 29.88万
  • 项目类别:
    Grant-in-Aid for Scientific Research (C)
NeuroGrid: a scalable system for large-scale recording of action potentials from the brain surface
NeuroGrid:用于大规模记录大脑表面动作电位的可扩展系统
  • 批准号:
    9357409
  • 财政年份:
    2016
  • 资助金额:
    $ 29.88万
  • 项目类别:
{{ showInfoDetail.title }}

作者:{{ showInfoDetail.author }}

知道了